At time of first response assessment, 18 (58%) patients had any positive autoantibody titer, of which 14 (45.1%), 4 (12.9%), 3 (9.7%), and 3 (9.7%) patients were ANA, ENA, hepatopathy‐ or myositis autoantibody positive, respectively. The gene discussed is BTG3; the disease is Decreased liver function.